285 related articles for article (PubMed ID: 27696262)
1. Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma.
Laubach J; Kumar S
Cancer Treat Res; 2016; 169():145-167. PubMed ID: 27696262
[TBL] [Abstract][Full Text] [Related]
2. Treatment for patients with newly diagnosed multiple myeloma in 2015.
Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
[TBL] [Abstract][Full Text] [Related]
3. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
4. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Voorhees PM; Usmani SZ
Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
[TBL] [Abstract][Full Text] [Related]
5. Role of autologous bone marrow transplant in multiple myeloma.
Blanes M; de la Rubia J
Curr Opin Oncol; 2012 Nov; 24(6):733-41. PubMed ID: 23079784
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
7. Clinical treatment of newly diagnosed multiple myeloma.
Cejalvo MJ; de la Rubia J
Expert Rev Hematol; 2015 Oct; 8(5):595-611. PubMed ID: 26327587
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma.
Holstein SA; Liu H; McCarthy PL
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1113-29. PubMed ID: 25459182
[TBL] [Abstract][Full Text] [Related]
9. Evolving paradigms in the treatment of newly diagnosed multiple myeloma.
Larocca A; Palumbo A
J Natl Compr Canc Netw; 2011 Oct; 9(10):1186-96. PubMed ID: 21975915
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of newly diagnosed multiple myeloma in transplant-eligible patients].
Sakaida E
Rinsho Ketsueki; 2020; 61(9):1306-1316. PubMed ID: 33162530
[TBL] [Abstract][Full Text] [Related]
11. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.
Nathwani N; Larsen JT; Kapoor P
Curr Hematol Malig Rep; 2016 Apr; 11(2):127-36. PubMed ID: 26893062
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
Malard F; Harousseau JL; Mohty M
Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
[TBL] [Abstract][Full Text] [Related]
13. Optimal treatment strategies in myeloma: An argument against maintenance therapy after autologous stem cell transplantation.
Richter J; Biran N; Vesole D; Siegel D
Semin Oncol; 2016 Dec; 43(6):714-717. PubMed ID: 28061995
[TBL] [Abstract][Full Text] [Related]
14. Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.
Kumar SK; Buadi FK; Rajkumar SV
Blood; 2019 Feb; 133(7):652-659. PubMed ID: 30587528
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well.
Martino M; Morabito F
Expert Opin Biol Ther; 2015 Feb; 15(2):149-54. PubMed ID: 25435056
[TBL] [Abstract][Full Text] [Related]
16. Management of multiple myeloma in the newly diagnosed patient.
Mateos MV; San Miguel JF
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):498-507. PubMed ID: 29222298
[TBL] [Abstract][Full Text] [Related]
17. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
18. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.
Gay F; Engelhardt M; Terpos E; Wäsch R; Giaccone L; Auner HW; Caers J; Gramatzki M; van de Donk N; Oliva S; Zamagni E; Garderet L; Straka C; Hajek R; Ludwig H; Einsele H; Dimopoulos M; Boccadoro M; Kröger N; Cavo M; Goldschmidt H; Bruno B; Sonneveld P
Haematologica; 2018 Feb; 103(2):197-211. PubMed ID: 29217780
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of multiple myeloma in both transplant and non-transplant candidates.
Oriol A; Abril L; Ibarra G
Expert Rev Anticancer Ther; 2023 Jul; 23(7):685-698. PubMed ID: 37194283
[TBL] [Abstract][Full Text] [Related]
20. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Joks M; Jurczyszyn A; Machaczka M; Skotnicki AB; Komarnicki M
Eur J Haematol; 2015 Feb; 94(2):109-14. PubMed ID: 25039659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
